trigger brand semaglutide The upcoming expiry of the semaglutide patent in India in mid-March 2026 is expected to transform the country's diabetes treatment landscape. Ahead of this, industry experts predict that the development will open

📢 FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Patients and prescribers may still see intermittent and limited localized supply disruptions as the

20.15

★★★★☆4.8 (126)

📢 FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Patients and prescribers may still see intermittent and limited localized supply disruptions as the

25.83

★★★★★4.9 (98)

Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders

23.10

★★★★★5.0 (157)

FDA Approves Oral Semaglutide: First GLP-1 Weight Loss Pill

27.04

★★★★★4.7 (84)

Weight‑loss drugs such as Ozempic may trigger temporary hair loss in some people, particularly during periods of rapid weight reduction, a new study suggests. Details: https://wgntv.com/news/medical-watch/glp-1s-and-hair-loss-study-finds-new-link/

24.71

★★★★★4.9 (203)

Ozempic just got cheaper in India. But this isn't just about one drug. After Novo Nordisk's patent expiry, multiple Indian pharma companies have launched lower-cost versions of semaglutide- the molecule used for

24.69

★★★★★5.0 (176)

Last week's expiry of the patent for semaglutide—the active ingredient in Novo Nordisk's blockbuster drugs that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions

22.76

★★★★★4.8 (132)